Get the Stockscreener App
46.27
0.42%
0.20
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $46.27, with a volume of 11.94M.
It is up +0.42% in the last 24 hours and up +1.79% over the past month.
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$46.07
Open:
$46.2
24h Volume:
11.94M
Relative Volume:
0.84
Market Cap:
$94.19B
Revenue:
$48.03B
Net Income/Loss:
$6.05B
P/E Ratio:
15.62
EPS:
2.9615
Net Cash Flow:
$14.58B
1W Performance:
+6.63%
1M Performance:
+1.79%
6M Performance:
-8.51%
1Y Performance:
-14.83%
1-Day Range:
$45.51
$46.66
1-Week Range:
$42.52
$46.66
52-Week Range:
$42.52
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
46.27 | 93.79B | 48.03B | 6.05B | 14.58B | 2.9615 |
|
LLY
Lilly Eli Co
|
897.80 | 772.28B | 59.42B | 18.41B | -50.20M | 20.22 |
|
JNJ
Johnson Johnson
|
186.80 | 455.04B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
212.74 | 385.18B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
123.24 | 237.53B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
83.36 | 214.76B | 63.99B | 19.05B | 14.72B | 7.5596 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-05-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Apr-22-25 | Initiated | Piper Sandler | Overweight |
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership - inkl
Bristol-Myers Squibb stock rises 7% after clean earnings beat By Investing.com - Investing.com Nigeria
United States Vitiligo Forecast Report 2025: A $320+ Million Market by 2033 Featuring Incyte, BMS, Clinuvel Pharmaceuticals, Astellas Pharma, Baxter, Pfizer, Dr. Reddy's LaboratoriesResearchAndMarkets.com - Business Wire
US Cancer Immunotherapy Forecast and Company Analysis Report 2025-2033 Featuring Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Pfizer, Novartis, Johnson & Johnson, Eli Lily Co, Seattle GeneticsResearchAndMarkets.com - FinancialContent
Bristol-Myers Squibb stock rises 7% after clean earnings beat - Investing.com
Cleveland-Cliffs, Meta And Rocket On CNBC's 'Final Trades' - Benzinga
Verity Asset Management Inc. Trims Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Showcases New Long-Term and Real-World Data From Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2025 - Business Wire
BioNTech raises 2025 revenue guidance after Bristol Myers deal By Investing.com - Investing.com Nigeria
BioNTech raises 2025 revenue guidance after Bristol Myers deal - Investing.com
BioNTech lifts 2025 revenue guidance on BMS partnership payment - Reuters
BioNTech Raises Sales Outlook on Boost from Bristol Payments - Bloomberg.com
Bristol Myers Squibb Co Announces $7 Billion Cash Tender Offers - TradingView
Bristol Myers Squibb Announces Cash Tender Offers to Purchase Certain Notes - The AI Journal
Published on: 2025-11-02 22:42:16 - newser.com
How Bristol Myers Squibb Company (BRM) stock moves in volatile trading sessionsQuarterly Risk Review & Weekly Market Pulse Alerts - newser.com
Syverson Strege & Co Acquires New Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Assetmark Inc. Lowers Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
What’s the recovery path for long term holders of Bristol Myers Squibb Company Equity RightTrade Signal Summary & Technical Pattern Alert System - newser.com
Bristol-Myers Squibb Company (NYSE:BMY) Q3 2025 Earnings Call Transcript - Insider Monkey
Can Bristol Myers Squibb Company stock hit record highs againExit Point & Entry Point Confirmation Signals - newser.com
Bristol Myers Squibb Co. Hits New 52-Week Low at $42.52 - Markets Mojo
Bristol Myers Squibb Company recovery potential after sell offWeekly Market Report & Risk Controlled Daily Trade Plans - newser.com
Is Bristol Myers Squibb Company Celegne Contingent stock a fit for income portfolios2025 Market Overview & Comprehensive Market Scan Insights - newser.com
Bristol-Myers Squibb Company (BMY.MX) stock price, news, quote and history - Yahoo! Finance UK
Bristol Myers Squibb (NYSE:BMY) Posts Earnings Results, Beats Expectations By $0.11 EPS - MarketBeat
Bristol Myers Squibb Stock Hits Day High with 7.09% Surge - Markets Mojo
S&P 500 Falls 0.99% Amid 1,651 Advancing Stocks; Bristol Myers Soars 7.09% - Markets Mojo
Bristol-Myers Squibb Tops Forecasts But Leaves Questions Unanswered - Finimize
Retirement Systems of Alabama Has $60.37 Million Stake in Bristol Myers Squibb Company $BMY - MarketBeat
New launches focus of latest financial prints at BMS, Merck & Co. - FirstWord Pharma
Bristol-Myers Squibb Company Confirms Efficacy and Safety of Sotyktu for Psoriatic Arthritis and Lupus with New Long-Term Data - Insider Monkey
Bristol-Myers Squibb Co (BMY) Q3 2025 Earnings: Revenue Surpasse - GuruFocus
Bristol-Myers Squibb Shares Rally on Strong Quarterly Performance - AD HOC NEWS
Will Bristol Myers Squibb Company (BRM) stock beat growth indexesBuy Signal & Momentum Based Trading Signals - newser.com
Bristol-Myers Squibb Company (BMY) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Research Alert: CFRA Keeps Buy View On Shares Of Bristol-myers Squibb Company - 富途牛牛
Bristol-Myers Squibb Company (BMY) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Bristol-Myers Sets $160 Million Tax Reserve for Transfer Pricing - news.bloombergtax.com
Bristol-Myers Squibb Co (BMY) Q3 2025 Earnings Call Highlights: Strong Growth and Strategic ... - Yahoo Finance
Bristol-Myers Squibb Company (BMY) Q3 2025 Earnings Call Transcript Summary - 富途牛牛
Bladder Cancer MarketGlobal and Regional Analysis and Forecast (2025-2035) Featuring Merck & Co., Bristol Myers Squibb, Astellas Pharma, AstraZeneca, and Johnson & Johnson - Yahoo Finance
BRISTOL MYERS SQUIBB CO SEC 10-Q Report - TradingView
Bristol rises on 2025 guidance raises, Q3 beats driven by Eliquis growth - MSN
Bristol Myers tries to temper anxiety over upcoming Cobenfy readout, unveils suite of PD-1xVEGF bispecific trials - Endpoints News
BMS Battles ‘Deeply Ingrained’ Prescribing Habits in Schizophrenia as Cobenfy Misses Q3 Estimates - BioSpace
December 12th Options Now Available For Bristol Myers Squibb (BMY) - Nasdaq
BMY Beats on Q3 Earnings and Sales, Raises 2025 Sales View - TradingView
Bristol Myers Squibb (NYSE:BMY) Surges on Q3 Earnings Beat and Raised Outlook – What’s Next for BMY Stock? - ts2.tech
Bristol Myers Squibb Outpaces Expectations With Strong New Drug Sales - Finimize
Bristol Myers beats quarterly revenue estimates on strong Opdivo sales - Reuters
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):